Last reviewed 2026-04-22 · How we verify

BPI-7711

BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.

BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers).

At a glance

Mechanism of action

BPI-7711 targets FGFR mutations and fusions that drive proliferation in certain solid tumors. By inhibiting FGFR kinase activity, the drug suppresses downstream signaling pathways critical for tumor growth and survival. This approach is particularly relevant in cancers with FGFR alterations, where the pathway is oncogenically activated.

Approved indications

• FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea
• Stomatitis

Key clinical trials

• A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients (PHASE3)
• A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive (PHASE2)
• BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer (PHASE1, PHASE2)
• A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 (PHASE1)
• A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.